Sporting News' NBA experts break down the 2025 playoff bracket, with predictions for every series from the play-in tournament ...

Where the fantasy value of a rookie class is concerned, talent is incredibly important. But like opening a successful ...

The Hawks have been up-and-down since losing Jalen Johnson, and the Magic haven't been ... That matchup probably won't happen — the Warriors should beat up a slumping Grizzlies team in that ...

NBA playoffs are as wide open as we've seen in a long time. The Celtics are a popular pick to repeat, but the Cavaliers ...

Johnson & Johnson (NYSE:JNJ) opened the pharmaceutical earnings season on Tuesday by boosting its full-year sales forecast after posting stronger-than-expected first-quarter results. The ...

Johnson & Johnson (JNJ) came out with quarterly earnings of $2.77 per share, beating the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.71 per share a year ago.

Johnson & Johnson (JNJ) shares rose 0.4% in premarket trades after the medical-technology and drug company beat Wall Street's profit and revenue estimates and raised its full-year sales guidance.

Johnson & Johnson still raised its outlook for sales in 2025, while keeping its profit guidance intact. The company also reported first-quarter results that beat expectations and raised its ...

Johnson & Johnson (JNJ ... costs and drive sales growth across key product lines. Despite the earnings beat, J&J’s stock experienced a 0.39% decline in pre-market trading, closing at $154. ...

J&J beat quarterly profit and revenue expectations and raised its dividend but didn't change its profit outlook, and the stock pulled back Johnson & Johnson beat Wall Street's expectations for ...

Johnson & Johnson (NYSE:JNJ) opened the pharmaceutical earnings season on Tuesday by boosting its full-year sales forecast after posting stronger-than-expected first-quarter results. The announcement ...